Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0GNXLK)
| ADC Name |
SHR-4849
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SHR-4849; IDE849; HRA00130-C004
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Hengrui Pharmaceuticals (Originator);IDEAYA Biosciences
|
|||||
| Drug Status |
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
SHR-2495
|
Antibody Info | ||||
| Antigen Name |
Delta-like protein 3 (DLL3)
|
Antigen Info | ||||
| Payload Name |
SHR9265
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
rezetecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible subjects were 18-75 years with advanced solid tumors (measurable per RECIST 1.1), ECOG 0-1, life expectancy ≥3 months, and adequate organ function. Key exclusions: CNS metastasis, recent malignancies (5 years), uncontrolled pain/effusions, severe CVD/interstitial lung disease, active HBV/HCV/HIV, unresolved prior toxicities (CTCAE >Grade 1), recent anticancer therapy/surgery (4 weeks), pregnancy, or drug allergies. Additional exclusions per investigator discretion.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06443489 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I ,Open-label, Multicenter Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Efficacy of SHR-4849 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
The study assessed dose-limiting toxicities (DLTs) during a 21-day observation period post-dosing, along with AEs/SAEs graded per NCI-CTCAE v5.0 monitored for 24 months. The MTD/MAD and RP2D were determined after subjects in escalation/expansion phases completed ≥1 dosing cycle (24-month follow-up).
|
||||
| Other Endpoint |
Efficacy outcomes included ORR (CR+PR), DCR (CR+PR+SD), DoR (time to progression/death), and PFS (treatment-initiation to progression/death)-all per RECIST 1.1 over 24 months-plus OS (30-month follow-up from treatment initiation).
|
||||